B. Roehr
Impact in
- Infectious Diseases top 10%
- HIV/AIDS Research and Interventions
- Viral Infections and Vectors
Papers in
-
- Healthcare Policy and Management 23
- Health Systems, Economic Evaluations, Quality of Life 15
- Pharmaceutical Economics and Policy 14
-
- Primary Care and Health Outcomes 16
- Health Services Management and Policy 12
- Journals
- BMJ (78 papers)Proceedings of the National Academy of Sciences (1 paper)PubMed (7 papers)BMJ (84 papers)
- Partner nations
- United States
In The Last Decade
B. Roehr
137 papers receiving 648 citations
Peers
Comparison fields: 5 of 133
- Medical Terminology 2
- Infectious Diseases 127
- Virology 29
- Microbiology 27
- General Health Professions 104
Countries citing papers authored by B. Roehr
This map shows the geographic impact of B. Roehr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Roehr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Roehr more than expected).
Fields of papers citing papers by B. Roehr
This network shows the impact of papers produced by B. Roehr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Roehr. The network helps show where B. Roehr may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 171 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Fomivirsen approved for CMV retinitis. | 1998 | 127 |
| 2 | 2005 | 36 | |
| 3 | 2010 | 24 | |
| 4 | 2012 | 24 | |
| 5 | 2012 | 21 | |
| 6 | 2009 | 20 | |
| 7 | 2021 | 17 | |
| 8 | 2010 | 17 | |
| 9 | 2010 | 13 | |
| 10 | 2020 | 12 | |
| 11 | 2012 | 12 | |
| 12 | 2012 | 12 | |
| 13 | 2009 | 11 | |
| 14 | The many faces of human growth hormone. | 2003 | 10 |
| 15 | 2012 | 10 | |
| 16 | 2013 | 10 | |
| 17 | 2012 | 9 | |
| 18 | 2009 | 9 | |
| 19 | FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration. | 1998 | 9 |
| 20 | 2011 | 9 |
About B. Roehr
B. Roehr is a scholar working on Economics and Econometrics, General Health Professions, Public Health, Environmental and Occupational Health, Infectious Diseases and Pharmacology, having authored 171 papers that have together received 709 indexed citations. Recurring topics across this work include Healthcare Policy and Management (23 papers), Pharmaceutical industry and healthcare (20 papers), Primary Care and Health Outcomes (16 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers), Pharmaceutical Economics and Policy (14 papers), Health Services Management and Policy (12 papers), Global Public Health Policies and Epidemiology (12 papers) and HIV/AIDS Research and Interventions (11 papers). The work is most often cited by research in Medical Terminology (2 citations), Infectious Diseases (127 citations), Virology (29 citations), Microbiology (27 citations) and General Health Professions (104 citations). B. Roehr has collaborated with scholars based in United States. Their work appears in journals such as BMJ, Proceedings of the National Academy of Sciences, PubMed and BMJ.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.